MYGN vs. FOLD, BCRX, CLDX, DVAX, INVA, MNKD, NVAX, OPK, GERN, and RGLS
Should you be buying Myriad Genetics stock or one of its competitors? The main competitors of Myriad Genetics include Amicus Therapeutics (FOLD), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Innoviva (INVA), MannKind (MNKD), Novavax (NVAX), OPKO Health (OPK), Geron (GERN), and Regulus Therapeutics (RGLS). These companies are all part of the "biotechnology" industry.
Myriad Genetics vs. Its Competitors
Myriad Genetics (NASDAQ:MYGN) and Amicus Therapeutics (NASDAQ:FOLD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability.
99.0% of Myriad Genetics shares are held by institutional investors. 2.1% of Myriad Genetics shares are held by insiders. Comparatively, 2.2% of Amicus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Myriad Genetics currently has a consensus target price of $14.38, suggesting a potential upside of 187.69%. Amicus Therapeutics has a consensus target price of $16.22, suggesting a potential upside of 174.49%. Given Myriad Genetics' higher possible upside, research analysts plainly believe Myriad Genetics is more favorable than Amicus Therapeutics.
Myriad Genetics has a beta of 1.91, meaning that its share price is 91% more volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500.
Amicus Therapeutics has lower revenue, but higher earnings than Myriad Genetics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Amicus Therapeutics had 12 more articles in the media than Myriad Genetics. MarketBeat recorded 15 mentions for Amicus Therapeutics and 3 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 1.49 beat Amicus Therapeutics' score of 0.94 indicating that Myriad Genetics is being referred to more favorably in the media.
Amicus Therapeutics has a net margin of -5.41% compared to Myriad Genetics' net margin of -12.20%. Amicus Therapeutics' return on equity of 4.67% beat Myriad Genetics' return on equity.
Summary
Amicus Therapeutics beats Myriad Genetics on 10 of the 16 factors compared between the two stocks.
Get Myriad Genetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MYGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Myriad Genetics Competitors List
Related Companies and Tools
This page (NASDAQ:MYGN) was last updated on 7/16/2025 by MarketBeat.com Staff
Free MYGN Stock Alerts